← Companies|ImmunoGen (AbbVie)
Im

ImmunoGen (AbbVie)

Waltham MAFounded 1981600 employees
Private CapbiotechAcquiredOncology
Platform: Mirvetuximab ADC
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
MiriinavolisibIMM-7408Phase 33mAbNectin-4HER2MDDPBC
IMM-7144IMM-7144Approved2ERTPI3KαAnti-TauBladder CaEoE
IMM-8177IMM-8177Phase 11Fusion ProteinMeninBCL-2iRSV
IMM-7074IMM-7074Phase 1/22Small MoleculeWRNGLP-1/GIPALLDravet
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (5)
2025-02-13
IMM-7074 Ph2 Data
Dravet
Past
2025-03-15
IMM-8177 Interim
RSV
Past
2030-07-23
Miriinavolisib Ph3 Readout
PBC
Ph3 Readout
2030-12-02
IMM-7144 Ph3 Readout
EoE
Ph3 Readout
2031-02-22
IMM-7074 Ph2 Data
ALL
Ph2 Data